APP Pharmaceuticals Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc., (APCVZ) announced that it has received U.S. Food and Drug Administration or FDA approval to market Sumatriptan Succinate Injection, USP, in two dosage strengths.
APP said it will package Sumatriptan Succinate Injection in pre-filled syringes of 4 mg (base) /0.5 mL and 6 mg (base) / 0.5 mL. .
APP's Sumatriptan Succinate Injection is AP-rated, bar-coded and latex-free. The company said that Sumatriptan Succinate Injection is a vascular headache suppressant indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster headache episodes.
For comments and feedback: editorial@rttnews.com